research has shown that HIV-HCV
coinfected people tend to experience faster liver
disease progression and respond less well to interferon-based
therapy that patients with HCV
alone, but there is little data on the rate and
timing of hepatitis C virus (HCV) relapse after completing
the present retrospective study, researchers at Hospital
Carlos III in Madrid, Spain looked at medical record
from 604 chronic hepatitis C patients -- 386 of whom
were also HIV positive
-- treated with pegylated
interferon plus ribavirin between 2001 and 2007.
coinfected patients achieved an end-of-treatment
response less often than HCV monoinfected patients
(37% vs 61%, respectively).
patients were also more likely than monoinfected
patients to experience relapse following treatment
(33% vs 22%, respectively).
occurred more often in patients with hard-to-treat
HCV genotypes 1 or 4, compared with genotypes 2
both HIV positive and HIV negative participants,
HCV relapse, when it occurred, usually happened
before week 12 post-treatment.
patients tested HCV positive after post-treatment
week 12, but genetic analysis indicated that 2 of
these cases likely were due to re-infection rather
individuals were both less likely to respond by
the end of treatment and more likely to relapse, they
had a lower likelihood of SVR
-- or a cure -- defined as continued undetectable HCV
viral load 24 weeks after completion of therapy, the
of Infectious Diseases, Service of Hepatology and CIBERehd,
and Service of Pharmacy, Hospital Carlos III, Madrid,
Spain; Laboratory of Molecular Epidemiology of Infectious
Diseases, National Centre for Microbiology, Instituto
de Salud Carlos III, Madrid, Spain.
Medrano, P Barreiro, S Resino, and others. Rate and
timing of hepatitis C virus relapse after a successful
course of pegylated interferon plus ribavirin in HIV-infected
and HIV-uninfected patients. Clinical Infectious
Diseases 49(9): 1397-1401. November 1, 2009. (Abstract).